ADICET BIO INC (ACET)       8.96  +0.07 (+0.79%)

Company Profile

Adicet Bio, Inc. is a biotechnology company, which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company is headquartered in Boston, Massachusetts and currently employs 86 full-time employees. The company went IPO on 2018-01-26. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CAR) and T cell receptor-like antibodies (TCRL), to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response and improve persistence for durable activity in patients. Its lead product candidate, ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is under Phase I study for the treatment of Non-Hodgkin's Lymphoma. Its pipeline also includes ADI-002, an allogeneic gamma delta CAR-T cell therapy expressing a GPC3-targeted CAR and a cell intrinsic soluble form of interluiken-15, for the treatment of solid tumors. In addition, it is engaged in discovery and preclinical stage activities of its pipeline of product candidates for both hematological malignancies and solid tumors.

Company Info

ADICET BIO INC

200 Berkeley Street, 19Th Floor

Boston MASSACHUSETTS 02116

P: 16174822333.0

CEO: Chen Schor

Employees: 86

Website: https://www.adicetbio.com/